Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 25 |
| Active Pipeline (Recruiting Now) | 13 (9) |
| Completed vs Stopped Early | 5 / 3 (12.0%) |
| Median Closed Actual Enrollment | 49 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Leicester Royal Infirmary | Leicester | 6 |
| University Hospital of Wales | Cardiff, Wales | 5 |
| Derriford Hospital | Plymouth, Devon | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05848765 | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | Phase II | RECRUITING |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD) | Phase II | RECRUITING |
| NCT04116502 | MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera | Phase III | RECRUITING |
| NCT05991388 | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | Phase II/III | RECRUITING |
| NCT04256798 | Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the University of Birmingham Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.